Loading events...
Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Key Innovative brands continue to drive growth, with revenues +33% YoY in LC to $830 million, and to provide value to diverse and critical patient populations: AUSTEDO ® – shows continued strong growth with global revenues of $618 million in Q3 2025 (+38% in LC YoY).
Wednesday, November 5, 2025
Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Key Innovative brands continue to drive growth, with revenues +33% YoY in LC to $830 million, and to provide value to diverse and critical patient populations: AUSTEDO ® – shows continued strong growth with global revenues of $618 million in Q3 2025 (+38% in LC YoY).
Are you the organizer?
Claim this event to edit details, see analytics, and get leads
Receive curated event recommendations based on your interests.
See how WebMobi helps you manage registration, check-in, and analytics.
Request a DemoOr start free →Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS takes place on Wednesday, November 5, 2025. All times are in UTC.
WebMobi provides event registration, ticketing, mobile apps, check-in, and analytics — all with zero platform fees.
Get curated B2B events, AI-powered insights, and industry trends delivered to your inbox